SCHEMBL20134752

SCHEMBL20134752

Cc1ccc(C2(C(C)C)NC(=O)NC2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 1/20 0.45
CYP2C9 P11712 2/20 0.39
CACNA1F O60840 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
HTR2A P28223 1/20 0.39
HRH1 P35367 1/20 0.39
SCN1A P35498 1/20 0.39
SCN4A P35499 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
CACNA1D Q01668 1/20 0.39
KCNH2 Q12809 1/20 0.39
CACNA1S Q13698 1/20 0.39
CACNA1C Q13936 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN2A Q99250 1/20 0.39
SCN3A Q9NY46 1/20 0.39
AKR1B1 P15121 3/20 0.37
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4232196 0.85 CYP2C9 (0.55) ADAM17CYP2C9CACNA1FALDH1A1MAPT
SCHEMBL10599902 0.82 ADAM17 (0.40) ADAM17CYP2C9CACNA1FALDH1A1MAPT
SCHEMBL20134833 0.81 CYP2C9 (0.41) ADAM17CYP2C9CACNA1FALDH1A1MAPT
SCHEMBL20134941 0.80 AKR1B1 (0.40) CYP2C9CACNA1FALDH1A1MAPTHTR2A
SCHEMBL20134939 0.80 AKR1B1 (0.40) CYP2C9CACNA1FALDH1A1MAPTHTR2A
SCHEMBL20135355 0.79 AKR1B1 (0.36) CYP2C9CACNA1FALDH1A1MAPTHTR2A
SCHEMBL20135356 0.79 AKR1B1 (0.36) CYP2C9CACNA1FALDH1A1MAPTHTR2A
SCHEMBL20134891 0.78 MMP14 (0.40) ADAM17CYP2C9CACNA1FALDH1A1MAPT
SCHEMBL20135714 0.76 KMT2A (0.61) ALDH1A1MEN1KMT2A
SCHEMBL10521481 0.73 CYP2C9 (0.64) ADAM17CYP2C9CACNA1FALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 ADAM17 36/4885CYP2C9 139/4885CACNA1F 4562/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 ADAM17 39/4885CYP2C9 97/4885CACNA1F 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.